RenovoRx, Inc. (NASDAQ:RNXT - Get Free Report) insider Ramtin Agah purchased 26,000 shares of the company's stock in a transaction that occurred on Tuesday, April 8th. The stock was bought at an average price of $0.84 per share, for a total transaction of $21,840.00. Following the transaction, the insider now directly owns 1,048,460 shares in the company, valued at $880,706.40. This trade represents a 2.54 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
RenovoRx Stock Up 3.7 %
Shares of RNXT stock opened at $0.83 on Thursday. The business has a 50 day moving average of $1.02 and a two-hundred day moving average of $1.14. RenovoRx, Inc. has a 52 week low of $0.75 and a 52 week high of $1.69. The company has a market cap of $19.92 million, a P/E ratio of -1.46 and a beta of 1.12.
RenovoRx (NASDAQ:RNXT - Get Free Report) last posted its quarterly earnings results on Monday, March 31st. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). The business had revenue of $0.04 million for the quarter, compared to analysts' expectations of $0.17 million. Analysts expect that RenovoRx, Inc. will post -0.4 EPS for the current fiscal year.
Institutional Trading of RenovoRx
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Citadel Advisors LLC bought a new stake in shares of RenovoRx during the fourth quarter valued at approximately $49,000. Renaissance Technologies LLC bought a new stake in shares of RenovoRx during the fourth quarter worth $84,000. Finally, Geode Capital Management LLC grew its position in RenovoRx by 61.9% in the third quarter. Geode Capital Management LLC now owns 232,937 shares of the company's stock valued at $247,000 after purchasing an additional 89,018 shares in the last quarter. Institutional investors own 3.10% of the company's stock.
Analysts Set New Price Targets
Separately, HC Wainwright reaffirmed a "buy" rating and issued a $3.00 target price on shares of RenovoRx in a research note on Friday, April 4th.
Check Out Our Latest Research Report on RenovoRx
RenovoRx Company Profile
(
Get Free Report)
RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
